FALSE2024Q10001083446--12-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesasth:segmentxbrli:pureasth:financial_ratio00010834462024-01-012024-03-3100010834462024-04-290001083446asth:AlliedPacificOfCaliforniaIPAMember2024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMember2023-12-3100010834462024-03-3100010834462023-12-310001083446us-gaap:NonrelatedPartyMember2024-03-310001083446us-gaap:NonrelatedPartyMember2023-12-310001083446us-gaap:RelatedPartyMember2024-03-310001083446us-gaap:RelatedPartyMember2023-12-310001083446us-gaap:SeriesAPreferredStockMember2024-03-310001083446us-gaap:SeriesAPreferredStockMember2023-12-310001083446us-gaap:SeriesBPreferredStockMember2024-03-310001083446us-gaap:SeriesBPreferredStockMember2023-12-310001083446us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-03-310001083446us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-12-310001083446asth:HealthCareCapitationRevenueMember2024-01-012024-03-310001083446asth:HealthCareCapitationRevenueMember2023-01-012023-03-310001083446us-gaap:HealthCareOtherMember2024-01-012024-03-310001083446us-gaap:HealthCareOtherMember2023-01-012023-03-310001083446us-gaap:ManagementServiceMember2024-01-012024-03-310001083446us-gaap:ManagementServiceMember2023-01-012023-03-310001083446us-gaap:HealthCarePatientServiceMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMember2023-01-012023-03-3100010834462023-01-012023-03-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2023-12-310001083446us-gaap:CommonStockMember2023-12-310001083446us-gaap:AdditionalPaidInCapitalMember2023-12-310001083446us-gaap:RetainedEarningsMember2023-12-310001083446us-gaap:NoncontrollingInterestMember2023-12-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2024-01-012024-03-310001083446us-gaap:RetainedEarningsMember2024-01-012024-03-310001083446us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001083446us-gaap:CommonStockMember2024-01-012024-03-310001083446us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2024-03-310001083446us-gaap:CommonStockMember2024-03-310001083446us-gaap:AdditionalPaidInCapitalMember2024-03-310001083446us-gaap:RetainedEarningsMember2024-03-310001083446us-gaap:NoncontrollingInterestMember2024-03-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2022-12-310001083446us-gaap:CommonStockMember2022-12-310001083446us-gaap:AdditionalPaidInCapitalMember2022-12-310001083446us-gaap:RetainedEarningsMember2022-12-310001083446us-gaap:NoncontrollingInterestMember2022-12-3100010834462022-12-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2023-01-012023-03-310001083446us-gaap:RetainedEarningsMember2023-01-012023-03-310001083446us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001083446us-gaap:CommonStockMember2023-01-012023-03-310001083446us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001083446us-gaap:NoncontrollingInterestMemberasth:MezzanineMember2023-03-310001083446us-gaap:CommonStockMember2023-03-310001083446us-gaap:AdditionalPaidInCapitalMember2023-03-310001083446us-gaap:RetainedEarningsMember2023-03-310001083446us-gaap:NoncontrollingInterestMember2023-03-3100010834462023-03-310001083446asth:CommercialMember2024-01-012024-03-310001083446asth:CommercialMember2023-01-012023-03-310001083446asth:MedicareMember2024-01-012024-03-310001083446asth:MedicareMember2023-01-012023-03-310001083446asth:MedicaidMember2024-01-012024-03-310001083446asth:MedicaidMember2023-01-012023-03-310001083446asth:OtherThirdPartiesMember2024-01-012024-03-310001083446asth:OtherThirdPartiesMember2023-01-012023-03-310001083446us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasth:PayorAMember2024-01-012024-03-310001083446us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasth:PayorAMember2023-01-012023-03-310001083446us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasth:PayorBMember2024-01-012024-03-310001083446us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberasth:PayorAMember2024-01-012024-03-310001083446us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberasth:PayorAMember2023-01-012023-12-310001083446asth:PayerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-03-310001083446asth:PayerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310001083446asth:AdvancedHealthManagementSystemsLPMember2024-03-312024-03-310001083446asth:PrimeCommunityCareOfCentralValleyIncMember2024-03-292024-03-290001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Member2024-01-312024-01-310001083446asth:AdvancedDiagnosticAndSurgicalCenterIncMember2024-01-010001083446asth:OtherAcquisitionsMember2024-03-312024-03-310001083446asth:TotalAcquisitionsMember2024-01-012024-03-310001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Member2024-01-310001083446asth:AdvancedHealthManagementSystemsLPMember2024-03-310001083446asth:OtherAcquisitionsMember2024-03-310001083446asth:TotalAcquisitionsMember2024-03-310001083446us-gaap:TrademarksMember2024-03-310001083446us-gaap:LicenseMember2024-03-310001083446srt:MinimumMemberasth:NetworkRelationshipsMember2024-03-310001083446asth:NetworkRelationshipsMembersrt:MaximumMember2024-03-310001083446asth:NetworkRelationshipsMember2024-03-310001083446asth:ManagementContractsMember2024-03-310001083446srt:MinimumMemberasth:MemberRelationshipsMember2024-03-310001083446asth:MemberRelationshipsMembersrt:MaximumMember2024-03-310001083446asth:MemberRelationshipsMember2024-03-310001083446asth:PatientManagementPlatformMember2024-03-310001083446us-gaap:TrademarksAndTradeNamesMember2024-03-310001083446us-gaap:DevelopedTechnologyRightsMember2024-03-310001083446us-gaap:TrademarksMember2023-12-310001083446srt:MinimumMemberasth:NetworkRelationshipsMember2023-12-310001083446asth:NetworkRelationshipsMembersrt:MaximumMember2023-12-310001083446asth:NetworkRelationshipsMember2023-12-310001083446asth:ManagementContractsMember2023-12-310001083446srt:MinimumMemberasth:MemberRelationshipsMember2023-12-310001083446asth:MemberRelationshipsMembersrt:MaximumMember2023-12-310001083446asth:MemberRelationshipsMember2023-12-310001083446asth:PatientManagementPlatformMember2023-12-310001083446us-gaap:TrademarksAndTradeNamesMember2023-12-310001083446us-gaap:DevelopedTechnologyRightsMember2023-12-310001083446asth:LasalleMedicalAssociatesIpaMember2024-03-310001083446asth:LasalleMedicalAssociatesIpaMember2023-12-310001083446asth:LasalleMedicalAssociatesIpaMember2024-01-012024-03-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2024-03-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2023-12-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2024-01-012024-03-310001083446asth:CAIPAMSOLLCMember2024-03-310001083446asth:CAIPAMSOLLCMember2023-12-310001083446asth:CAIPAMSOLLCMember2024-01-012024-03-310001083446asth:IHealthIncMember2024-03-310001083446asth:IHealthIncMember2023-12-310001083446asth:IHealthIncMember2024-01-012024-03-310001083446us-gaap:OtherInvesteesMember2024-03-310001083446us-gaap:OtherInvesteesMember2023-12-310001083446us-gaap:OtherInvesteesMember2024-01-012024-03-310001083446asth:LasalleMedicalAssociatesIpaMember2023-03-310001083446asth:LasalleMedicalAssociatesIpaMember2022-12-310001083446asth:LasalleMedicalAssociatesIpaMember2023-01-012023-03-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2023-03-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2022-12-310001083446asth:PacificMedicalImagingAndOncologyCenterIncMember2023-01-012023-03-310001083446asth:FiveThreeOneW.CollegeLLCMember2023-03-310001083446asth:FiveThreeOneW.CollegeLLCMember2022-12-310001083446asth:FiveThreeOneW.CollegeLLCMember2023-01-012023-03-310001083446asth:OneMSOLLCMember2023-03-310001083446asth:OneMSOLLCMember2022-12-310001083446asth:OneMSOLLCMember2023-01-012023-03-310001083446asth:CAIPAMSOLLCMember2023-03-310001083446asth:CAIPAMSOLLCMember2022-12-310001083446asth:CAIPAMSOLLCMember2023-01-012023-03-310001083446us-gaap:OtherInvesteesMember2023-03-310001083446us-gaap:OtherInvesteesMember2022-12-310001083446us-gaap:OtherInvesteesMember2023-01-012023-03-310001083446asth:IntraCareConvertiblePromissoryNoteReceivableMemberus-gaap:NotesReceivableMember2023-07-012023-07-310001083446asth:IntraCareConvertiblePromissoryNoteReceivableMemberus-gaap:NotesReceivableMember2023-07-310001083446asth:SeniorSecuredPromissoryNoteMemberasth:BassMedicalGroupMember2024-01-290001083446asth:TermLoanMember2024-03-310001083446asth:TermLoanMember2023-12-310001083446us-gaap:RevolvingCreditFacilityMember2024-03-310001083446us-gaap:RevolvingCreditFacilityMember2023-12-310001083446us-gaap:NotesPayableToBanksMember2024-03-310001083446us-gaap:NotesPayableToBanksMember2023-12-310001083446asth:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-06-162021-06-160001083446asth:AmendedCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-06-160001083446asth:AmendedCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:BridgeLoanMember2021-06-160001083446asth:AmendedCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2023-09-080001083446asth:AmendedCreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:LetterOfCreditMember2021-06-160001083446srt:MinimumMemberasth:AmendedCreditAgreementMemberasth:SecuredOvernightFinancingRateMember2021-06-162021-06-160001083446asth:AmendedCreditAgreementMemberasth:SecuredOvernightFinancingRateMembersrt:MaximumMember2021-06-162021-06-160001083446srt:MinimumMemberasth:AmendedCreditAgreementMemberus-gaap:BaseRateMember2021-06-162021-06-160001083446asth:AmendedCreditAgreementMemberus-gaap:BaseRateMembersrt:MaximumMember2021-06-162021-06-160001083446asth:AmendedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2024-03-310001083446us-gaap:LineOfCreditMemberasth:AmendedAndRestatedCreditAgreementMemberasth:TruistBankMember2023-11-030001083446us-gaap:RevolvingCreditFacilityMember2024-01-012024-03-310001083446us-gaap:RevolvingCreditFacilityMember2023-11-032023-11-030001083446us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SecuredDebtMemberasth:AmendedAndRestatedCreditAgreementMemberasth:TruistBankMember2023-11-030001083446us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberasth:AmendedAndRestatedCreditAgreementMemberasth:TruistBankMember2023-11-030001083446us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberasth:AmendedAndRestatedCreditAgreementMemberasth:TruistBankMember2023-11-030001083446asth:AmendedAndRestatedCreditAgreementMember2024-01-012024-03-310001083446srt:MinimumMemberasth:SecuredOvernightFinancingRateMember2024-01-012024-03-310001083446asth:SecuredOvernightFinancingRateMembersrt:MaximumMember2024-01-012024-03-310001083446srt:MinimumMemberus-gaap:BaseRateMember2024-01-012024-03-310001083446us-gaap:BaseRateMembersrt:MaximumMember2024-01-012024-03-310001083446asth:CreditAgreementMember2024-01-012024-03-310001083446asth:CreditAgreementMember2024-03-310001083446us-gaap:LineOfCreditMemberasth:AstranaMedicalMember2024-03-310001083446asth:SubordinatedLoanAgreementMemberus-gaap:SubordinatedDebtMember2021-05-310001083446asth:SubordinatedLoanAgreementMemberus-gaap:SubordinatedDebtMember2021-05-012021-05-310001083446asth:NewTermLoanMember2024-03-310001083446asth:NewTermLoanMember2023-12-310001083446asth:CreditAgreementMember2023-01-012023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ApcBusinessLoanAgreementMemberus-gaap:LineOfCreditMemberasth:PreferredBankMember2019-09-100001083446asth:AmendedCreditAgreementMemberus-gaap:StandbyLettersOfCreditMemberasth:TruistBankMember2024-03-310001083446asth:AmendedCreditAgreementMemberus-gaap:StandbyLettersOfCreditMemberasth:TruistBankMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberus-gaap:StandbyLettersOfCreditMember2024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberus-gaap:StandbyLettersOfCreditMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ApolloMedicalHoldingsIncMember2024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ApolloMedicalHoldingsIncMember2023-12-3100010834462023-01-012023-12-310001083446asth:CompanyAndAPCMember2023-12-310001083446asth:CompanyAndAPCMember2024-03-310001083446asth:CDSCMember2024-01-012024-03-310001083446asth:CDSCMember2023-01-012023-03-310001083446us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001083446us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001083446asth:StockAwardsAndUnitsMember2024-01-012024-03-310001083446asth:StockAwardsAndUnitsMember2023-01-012023-03-310001083446asth:ApcStockOptionMember2023-01-012023-03-310001083446us-gaap:RestrictedStockMember2024-01-012024-03-310001083446asth:PerformanceBasedRestrictedStockMember2024-01-012024-03-310001083446asth:EmployeeStockPurchasePlanMember2024-03-310001083446asth:LmaMemberasth:AHMCMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001083446asth:IHealthIncMember2023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:PmiocMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:PmiocMember2023-01-012023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:PmiocMember2024-03-310001083446asth:ProviderServicesMemberasth:SongPCMember2024-01-012024-03-310001083446asth:ProviderServicesMemberasth:SongPCMember2023-01-012023-03-310001083446asth:AstranaMedicalMemberasth:SongPCMember2024-03-310001083446asth:ArroyoVistaMemberasth:AHMCMemberus-gaap:RelatedPartyMember2024-01-012024-03-310001083446asth:ArroyoVistaMemberasth:AHMCMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001083446asth:ProviderServicesMemberasth:NetworkMedicalManagementMemberasth:ArroyoVistaMember2024-01-012024-03-310001083446asth:ProviderServicesMemberasth:NetworkMedicalManagementMemberasth:ArroyoVistaMember2023-01-012023-03-310001083446asth:ProfessionalMedicalCorporationMemberasth:OfficeLeaseMemberasth:AlliedPacificHoldingsInvestmentManagementLLCMember2024-01-012024-03-310001083446asth:ProfessionalMedicalCorporationMemberasth:OfficeLeaseMemberasth:AlliedPacificHoldingsInvestmentManagementLLCMember2023-01-012023-03-310001083446srt:ChiefExecutiveOfficerMemberasth:AlliedPacificHoldingsInvestmentManagementLLCMember2024-03-310001083446srt:ChiefExecutiveOfficerMemberasth:AlliedPacificHoldingsInvestmentManagementLLCMember2023-12-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:SunnyVillageCareCenterMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:SunnyVillageCareCenterMember2023-01-012023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMembersrt:DirectorMember2023-01-012023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMembersrt:DirectorMember2024-01-012024-03-310001083446asth:ProfessionalMedicalCorporationMemberasth:OfficeLeaseMemberasth:FirstCommonwealthPropertyLLCMember2024-01-012024-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:AHMCMember2024-01-012024-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:HSMSOMember2024-01-012024-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:AurionMember2024-01-012024-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:AHMCMember2023-01-012023-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:HSMSOMember2023-01-012023-03-310001083446asth:RelatedPartyTransactionRevenueRecognizedMemberasth:AurionMember2023-01-012023-03-310001083446asth:AHMCMemberasth:RelatedPartyTransactionExpensesIncurredMember2024-01-012024-03-310001083446asth:HSMSOMemberasth:RelatedPartyTransactionExpensesIncurredMember2024-01-012024-03-310001083446asth:AurionMemberasth:RelatedPartyTransactionExpensesIncurredMember2024-01-012024-03-310001083446asth:AHMCMemberasth:RelatedPartyTransactionExpensesIncurredMember2023-01-012023-03-310001083446asth:HSMSOMemberasth:RelatedPartyTransactionExpensesIncurredMember2023-01-012023-03-310001083446asth:AurionMemberasth:RelatedPartyTransactionExpensesIncurredMember2023-01-012023-03-310001083446asth:RelatedPartyTransactionRevenueExpenseNetMemberasth:AHMCMember2024-01-012024-03-310001083446asth:HSMSOMemberasth:RelatedPartyTransactionRevenueExpenseNetMember2024-01-012024-03-310001083446asth:AurionMemberasth:RelatedPartyTransactionRevenueExpenseNetMember2024-01-012024-03-310001083446asth:RelatedPartyTransactionRevenueExpenseNetMemberasth:AHMCMember2023-01-012023-03-310001083446asth:HSMSOMemberasth:RelatedPartyTransactionRevenueExpenseNetMember2023-01-012023-03-310001083446asth:AurionMemberasth:RelatedPartyTransactionRevenueExpenseNetMember2023-01-012023-03-310001083446us-gaap:HealthCareOtherMemberasth:AHMCMemberus-gaap:RelatedPartyMember2024-01-012024-03-310001083446us-gaap:HealthCareOtherMemberasth:AHMCMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001083446asth:AHMCMember2024-03-310001083446asth:AHMCMember2023-12-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:BoardMembersMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMemberasth:BoardMembersMember2023-01-012023-03-310001083446asth:BoardMembersWhoAreAlsoOfficersMemberasth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMember2024-01-012024-03-310001083446asth:BoardMembersWhoAreAlsoOfficersMemberasth:AlliedPacificOfCaliforniaIPAMemberasth:ProviderServicesMember2023-01-012023-03-310001083446asth:AlliedPacificOfCaliforniaIPAMember2024-01-012024-03-310001083446asth:AlliedPacificOfCaliforniaIPAMember2023-01-012023-12-310001083446us-gaap:RestrictedStockMember2024-01-012024-03-310001083446us-gaap:RestrictedStockMember2023-01-012023-03-310001083446us-gaap:PerformanceSharesMember2024-01-012024-03-310001083446us-gaap:PerformanceSharesMember2023-01-012023-03-310001083446us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001083446us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-01-010001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-01-012024-03-310001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-03-310001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001083446us-gaap:NonrelatedPartyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-03-310001083446us-gaap:NonrelatedPartyMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:RelatedPartyMember2024-03-310001083446us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:RelatedPartyMember2023-12-310001083446srt:MinimumMember2024-03-310001083446srt:MaximumMember2024-03-310001083446us-gaap:HealthCarePatientServiceMemberasth:CarePartnersMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446asth:CareDeliveryMemberus-gaap:HealthCarePatientServiceMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMemberasth:CareEnablementMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:HealthCarePatientServiceMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMemberus-gaap:IntersegmentEliminationMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMemberus-gaap:CorporateNonSegmentMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMemberasth:CarePartnersMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446asth:CareDeliveryMemberus-gaap:ProductAndServiceOtherMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMemberasth:CareEnablementMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:ProductAndServiceOtherMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMemberus-gaap:IntersegmentEliminationMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMemberus-gaap:CorporateNonSegmentMember2024-01-012024-03-310001083446us-gaap:ProductAndServiceOtherMember2024-01-012024-03-310001083446asth:CarePartnersMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446asth:CareDeliveryMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446asth:CareEnablementMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001083446us-gaap:IntersegmentEliminationMember2024-01-012024-03-310001083446us-gaap:CorporateNonSegmentMember2024-01-012024-03-310001083446us-gaap:HealthCarePatientServiceMemberasth:CarePartnersMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446asth:CareDeliveryMemberus-gaap:HealthCarePatientServiceMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:HealthCarePatientServiceMemberasth:CareEnablementMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:HealthCarePatientServiceMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:HealthCarePatientServiceMemberus-gaap:IntersegmentEliminationMember2023-01-012023-03-310001083446us-gaap:HealthCarePatientServiceMemberus-gaap:CorporateNonSegmentMember2023-01-012023-03-310001083446us-gaap:HealthCarePatientServiceMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMemberasth:CarePartnersMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446asth:CareDeliveryMemberus-gaap:ProductAndServiceOtherMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMemberasth:CareEnablementMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:ProductAndServiceOtherMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMemberus-gaap:IntersegmentEliminationMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMemberus-gaap:CorporateNonSegmentMember2023-01-012023-03-310001083446us-gaap:ProductAndServiceOtherMember2023-01-012023-03-310001083446asth:CarePartnersMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446asth:CareDeliveryMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446asth:CareEnablementMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001083446us-gaap:IntersegmentEliminationMember2023-01-012023-03-310001083446us-gaap:CorporateNonSegmentMember2023-01-012023-03-310001083446us-gaap:FairValueInputsLevel1Member2024-03-310001083446us-gaap:FairValueInputsLevel2Member2024-03-310001083446us-gaap:FairValueInputsLevel3Member2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:InterestRateCollarMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:InterestRateCollarMember2024-03-310001083446us-gaap:FairValueInputsLevel3Memberasth:InterestRateCollarMember2024-03-310001083446asth:InterestRateCollarMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:AAMGMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:AAMGMember2024-03-310001083446us-gaap:FairValueInputsLevel3Memberasth:AAMGMember2024-03-310001083446asth:AAMGMember2024-03-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel1Member2024-03-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel2Member2024-03-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel3Member2024-03-310001083446asth:VOMGMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:DmgMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:DmgMember2024-03-310001083446us-gaap:FairValueInputsLevel3Memberasth:DmgMember2024-03-310001083446asth:DmgMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:ApolloSunLabsManagementLLCMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:ApolloSunLabsManagementLLCMember2024-03-310001083446asth:ApolloSunLabsManagementLLCMemberus-gaap:FairValueInputsLevel3Member2024-03-310001083446asth:ApolloSunLabsManagementLLCMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:ADSCMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:ADSCMember2024-03-310001083446asth:ADSCMemberus-gaap:FairValueInputsLevel3Member2024-03-310001083446asth:ADSCMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:CFCMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:CFCMember2024-03-310001083446asth:CFCMemberus-gaap:FairValueInputsLevel3Member2024-03-310001083446asth:CFCMember2024-03-310001083446us-gaap:FairValueInputsLevel1Memberasth:PrimeCommunityCareMember2024-03-310001083446us-gaap:FairValueInputsLevel2Memberasth:PrimeCommunityCareMember2024-03-310001083446us-gaap:FairValueInputsLevel3Memberasth:PrimeCommunityCareMember2024-03-310001083446asth:PrimeCommunityCareMember2024-03-310001083446us-gaap:FairValueInputsLevel1Member2023-12-310001083446us-gaap:FairValueInputsLevel2Member2023-12-310001083446us-gaap:FairValueInputsLevel3Member2023-12-310001083446us-gaap:FairValueInputsLevel1Memberasth:AAMGMember2023-12-310001083446us-gaap:FairValueInputsLevel2Memberasth:AAMGMember2023-12-310001083446us-gaap:FairValueInputsLevel3Memberasth:AAMGMember2023-12-310001083446asth:AAMGMember2023-12-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel1Member2023-12-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel2Member2023-12-310001083446asth:VOMGMemberus-gaap:FairValueInputsLevel3Member2023-12-310001083446asth:VOMGMember2023-12-310001083446us-gaap:FairValueInputsLevel1Memberasth:DmgMember2023-12-310001083446us-gaap:FairValueInputsLevel2Memberasth:DmgMember2023-12-310001083446us-gaap:FairValueInputsLevel3Memberasth:DmgMember2023-12-310001083446asth:DmgMember2023-12-310001083446us-gaap:FairValueInputsLevel1Memberasth:ApolloSunLabsManagementLLCMember2023-12-310001083446us-gaap:FairValueInputsLevel2Memberasth:ApolloSunLabsManagementLLCMember2023-12-310001083446asth:ApolloSunLabsManagementLLCMemberus-gaap:FairValueInputsLevel3Member2023-12-310001083446asth:ApolloSunLabsManagementLLCMember2023-12-310001083446us-gaap:FairValueInputsLevel1Memberasth:InterestRateCollarMember2023-12-310001083446us-gaap:FairValueInputsLevel2Memberasth:InterestRateCollarMember2023-12-310001083446us-gaap:FairValueInputsLevel3Memberasth:InterestRateCollarMember2023-12-310001083446asth:InterestRateCollarMember2023-12-310001083446us-gaap:CertificatesOfDepositMember2024-01-012024-03-310001083446us-gaap:CertificatesOfDepositMember2024-03-310001083446us-gaap:CertificatesOfDepositMember2023-12-310001083446asth:InterestRateCollarMember2024-01-012024-03-310001083446asth:DMGAndSunLabsMember2024-01-012024-03-310001083446asth:DmgMember2024-03-310001083446asth:ApolloSunLabsManagementLLCMember2024-03-310001083446asth:ApolloSunLabsManagementLLCMember2023-12-310001083446asth:ApolloSunLabsManagementLLCMember2024-01-012024-03-310001083446asth:ApolloSunLabsManagementLLCMember2023-01-012023-03-310001083446asth:AAMGMember2022-10-310001083446asth:AAMGMemberasth:A2023MetricMember2024-01-012024-03-310001083446asth:AAMGMemberasth:A2024MetricMember2024-01-012024-03-310001083446us-gaap:OtherLiabilitiesMemberasth:AAMGMemberasth:A2023MetricMember2024-03-310001083446us-gaap:OtherLiabilitiesMemberasth:AAMGMemberasth:A2023MetricMember2023-12-310001083446asth:AAMGMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2024MetricMember2024-03-310001083446asth:AAMGMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2024MetricMember2023-12-310001083446asth:AAMGMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2023MetricMember2024-03-310001083446asth:AAMGMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2023MetricMember2023-12-310001083446asth:AdvancedDiagnosticAndSurgicalCenterIncMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2023MetricMember2024-03-310001083446asth:AdvancedDiagnosticAndSurgicalCenterIncMemberus-gaap:OtherNoncurrentLiabilitiesMemberasth:A2024MetricMember2024-03-310001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Memberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Memberasth:FirstMetricMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Memberasth:SecondMetricMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001083446asth:CommunityFamilyCareMedicalGroupIPAInc.Memberasth:ThirdMetricMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-310001083446asth:PCCCVMember2024-03-310001083446asth:IHealthPromissioryNoteMemberus-gaap:SubsequentEventMember2024-04-012024-04-010001083446asth:IHealthPromissioryNoteMemberus-gaap:SubsequentEventMember2024-04-010001083446asth:RevolverLoanMemberus-gaap:SubsequentEventMember2024-04-012024-05-09

Washington, D.C. 20549

For the quarterly period ended March 31, 2024

For the transition period from  ___ to ___.

(Exact name of registrant as specified in its charter)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of principal executive offices and zip code)

(Registrant’s telephone number, including area code) 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   ☒ Yes     ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   ☒   Yes     ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No As of April 29, 2024, there were 56,025,538 shares of common stock of the registrant, $0.001 par value per share, issued and outstanding, which includes 7,132,698 treasury shares that are owned by Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”), a consolidated affiliate of Astrana Health, Inc. These shares are legally issued and outstanding but treated as treasury shares for accounting purposes.

The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:

Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “we,” “us,” “our,” and similar words are references to Astrana Health, Inc., a Delaware corporation (“Astrana”), and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).

The Centers for Medicare & Medicaid Services (“CMS”) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (“APAACO”) in the ACO Realizing Equity, Access, and Community Health Model (“ACO REACH Model”) and ApolloMed MSSP I, Inc. in the Medicare Shared Savings Program (“MSSP”).

Trade names and trademarks of Astrana and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.

    This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions; any projections of earnings, revenue, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), Adjusted EBITDA, or other financial items, such as our projected capitation from CMS, our forward-looking guidance and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers, or acquisitions; any statements with respect to dividends or stock repurchases and timing, methods, and payment of same; any statements regarding the outlook of the ACO REACH Model, the MSSP, or strategic transactions; any statements regarding management’s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; our ability to maintain effective internal control over financial reporting and disclosure controls and procedures; any statements regarding potential changes to our tax structure; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “think,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “contemplate,” “budgeted,” “will,” or “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.

Forward-looking statements involve risks and uncertainties, many of which are difficult to predict and are outside of our control, and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2024, including the risk factors discussed under the heading “Risk Factors” in Part I, Item 1A thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. Any forward-looking statement made by the Company in this Form 10-Q speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(1)The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $717.5 million and $540.8 million as of March 31, 2024 and December 31, 2023, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $179.6 million and $146.0 million as of March 31, 2024 and December 31, 2023, respectively. These VIE balances do not include $299.5 million of investment in affiliates and $110.1 million of amounts due to affiliates as of March 31, 2024, and $273.2 million of investment in affiliates and $107.3 million of amounts due to affiliates as of December 31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. See Note 16 — “Variable Interest Entities (VIEs)” for further details.

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

(UNAUDITED)

(IN THOUSANDS, EXCEPT SHARE DATA)

(UNAUDITED)

(IN THOUSANDS)

(UNAUDITED)

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):

Unless the context dictates otherwise, references in these notes to the financial statements to the “Company,” “we,” “us,” “our,” and similar words are references to Astrana Health, Inc. (“Astrana”), formerly known as Apollo Medical Holdings, Inc., and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).

Headquartered in Alhambra, California, Astrana is a leading provider-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner. Together with Astrana’s affiliated physician groups and consolidated subsidiaries and VIEs, the Company provides value-based care enablement services and care delivery with its consolidated care partners to serve patients in California, Nevada, and Texas, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (“HMOs”), with a small portion of our revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists.

The Company’s three reportable segments are Care Partners, Care Delivery and Care Enablement, which are described as follows:

The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners aligned on a shared vision for coordinated care delivery. By leveraging the Company’s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations that take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare fee for service (“FFS”), Medicare Advantage, Medicaid, Commercial, and Exchange. Through the Company’s network of “independent practice associations” (“IPAs”), “accountable care organizations” (“ACOs”), and Restricted Knox-Keene licensed health plan, the Company’s healthcare delivery entities are responsible for coordinating and delivering high-quality care to the Company’s patients and ensuring continuity of care in Astrana’s ecosystem across age, stage of life, or life circumstance. Beginning in 2024, in addition to participating in the ACO REACH Model, the Company began participating in the Medicare Shared Savings Program (“MSSP”). The MSSP was created to promote accountability and improve coordination of care for Medicare beneficiaries.

The Company’s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company’s care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:

•Primary care clinics, including post-acute care services;

•Multi-specialty care clinics and medical groups, including hospitalist, intensivist, and physician advisory services, cardiac care and diagnostic testing, and specialized care for women’s health; and

•Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, and full-service labs.

The Company’s Care Enablement segment is an integrated, end-to-end clinical, operational, financial, and administrative platform powered by the Company’s proprietary technology suite that enhances the delivery of high-quality, value-based care to patients and leads to superior clinical and financial outcomes. The Company provides solutions to providers, including independent physicians, provider and medical groups, accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company’s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to hospital-shared risk-bearing entities, and across patient types, including Medicare, Medicaid, Commercial, and Exchange patients. This segment includes the Company’s wholly owned subsidiaries which operate as management services organizations (“MSOs”), which enter into long-term management and/or administrative services agreements with IPAs, ACOs, clinics, or independent providers. By leveraging the Company’s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.

The accompanying condensed consolidated balance sheet at December 31, 2023, has been derived from the Company’s audited condensed consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying unaudited condensed consolidated financial statements as of March 31, 2024, and for the three months ended March 31, 2024 and 2023, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited condensed consolidated financial statements and related notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 29, 2024. In the opinion of management, all material adjustments (consisting of normal recurring adjustments as well as intercompany accounts and transactions, which have been eliminated) considered necessary for a fair presentation have been made to make the condensed consolidated financial statements not misleading, as required by Regulation S-X, Rule 10-01. Operating results for the three months ended March 31, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, or any future periods.

The condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023, and the condensed consolidated statements of income for the three months ended March 31, 2024 and 2023, include Astrana’s wholly owned subsidiaries and consolidated variable interest entities (“VIEs”).

The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited condensed consolidated financial statements for the fiscal year ended December 31, 2023.

The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of hospital shared-risk and health plan shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.

The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.

As of March 31, 2024, the Company operates in three reportable segments:

•Care Partners;

•Care Delivery; and

•Care Enablement.

Refer to Note 1 — “Description of Business” and Note 18 — “Segments” to the condensed consolidated financial statements for information on the Company’s segments.

The Company’s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.

The Company maintains its cash in deposit accounts with several banks, which at times may exceed the insured limits of the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to any significant credit risk with respect to its cash and cash equivalents and restricted cash. As of March 31, 2024 and December 31, 2023, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately $353.6 million and $318.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company’s concentration of risk exposure.

The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.

The Company’s receivables – related parties are comprised of risk pool settlements, management fee income, and other receivables. Receivables – related parties are recorded and stated at the amount expected to be collected.

The Company’s loan receivables consists of promissory notes that accrue interest per annum. As of March 31, 2024, promissory notes are expected to be collected by their maturity dates.

Capitation and claims receivables relate to each health plan’s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s hospital shared-risk pool receivable, which is recorded quarterly based on reports received from the Company’s hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of receivables from fee-for-service (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.

The Company maintains reserves for potential credit losses on the receivables. Management reviews the composition of the Company’s receivables and analyzes historical bad debts, customer concentrations, customer creditworthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.

Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (“CECL”) model.

The Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The condensed consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payer type for the three months ended March 31, 2024 and 2023 (in thousands):

The Company had major payers that contributed the following percentages of net revenue:

*Less than 10% of total net revenues

The Company had major payers that contributed to the following percentages of receivables and receivables – related parties:

The Company receives payments from the following sources for services rendered:

•Commercial insurers;

•Federal government under the Medicare program administered by CMS;

•State governments under Medicaid and other programs;

•Other third-party payers (e.g., hospitals and IPAs); and Revenue primarily consists of the following:

•Individual patients and clients.

•Capitation revenue;

•Risk pool settlements and incentives;

•Management fee revenue; and

•FFS revenue.

Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer.

Beginning in 2024, Astrana participates in MSSP. The MSSP has multiple risk tracks, and Astrana is currently participating in the ENHANCED risk track. Under the MSSP Model, Astrana recruits a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage (the “MSSP Aligned Beneficiaries”). The Company’s MSSP Aligned Beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. CMS continues to pay participant and preferred providers on a fee-for-service basis for Medicare-covered services provided to MSSP Aligned Beneficiaries. The Company continues to bear risk on all Medicare expenditures (both in-network and out-of-network), excluding drug expenditures covered by Medicare Part D, based on a budgetary benchmark established with CMS. Astrana’s shared savings or losses in managing the Company’s beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to Astrana’s risk-share agreement with CMS, the Company is eligible to receive the surplus (“shared savings”) or is liable for the deficit (“shared losses”) according to the budgetary benchmark established by CMS based on Astrana’s efficiency, or lack thereof, in managing the expenditures associated with the Company’s MSSP Aligned Beneficiaries. The Company estimates the shared service revenue by analyzing the activities during the relevant time period in contemplation of the agreed upon benchmarks, metrics, performance criteria, and attribution criteria based on those and any other contractually defined factors. Revenue is not recorded and is constrained until the shared service revenue can be reasonably estimated by the Company and to the extent that it is probable that a significant reversal will not occur once any uncertainty associated with the variable consideration is subsequently resolved.

Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted for both items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the condensed consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the condensed consolidated financial statements.

In November 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for the Company’s annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures" to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. ASU 2023-09 is effective for the Company’s annual periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on its financial statement disclosures.

On March 31, 2024, the Company, through its wholly owned subsidiary, purchased all of the outstanding general and limited partnership interests of Advanced Health Management Systems, L.P. (“AHMS”). AHMS is engaged in the business of providing management, consulting, administrative and other support services to entities that provide or arrange for the provision of professional healthcare services. In addition, one of AHMS’s wholly owned subsidiaries is a Restricted Knox-Keene licensed health plan with members in the Los Angeles, California area. Total consideration for the acquisition was $63.9 million. As the cash was not paid on the closing date, the purchase price was accrued and presented within accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet as of March 31, 2024.

On March 29, 2024, the Company, through its consolidated subsidiary, acquired certain assets of Prime Community Care of Central Valley, Inc., a California professional medical corporation (“PCCCV”). Total consideration of the acquisition was approximately $10.3 million, consisting of cash funded upon the close date and contingent considerations of $2.3 million (“PCCCV contingent considerations”). Refer to Note 19 - “Fair Value Measurements of Financial Instruments” for additional information on contingent considerations.

On January 31, 2024, the Company, through its consolidated subsidiary, acquired certain assets of CFC. CFC is an IPA that manages the healthcare of members in the Los Angeles, California area. The group serves patients across Medicare, Medicaid, and Commercial payers. The total consideration for the purchase was $120.2 million, consisting of $91.0 million cash funded upon the close date, $22.0 million of the Company’s common stock, resulting in the issuance of 631,712 shares of common stock., and contingent considerations of $7.3 million (“CFC contingent considerations”). Refer to Note 19 - “Fair Value Measurements of Financial Instruments” for additional information on contingent considerations.

On January 1, 2024, the Company acquired 95% of the equity interest of Advanced Diagnostic and Surgical Center, Inc. (“ADSC”). ADSC is a diagnostic and surgical center that also provides ambulatory surgery services. The total consideration consisted of cash funded upon close of the transaction and contingent considerations of $3.6 million (“ADSC contingent considerations”). Refer to Note 19 - “Fair Value Measurements of Financial Instruments” for additional information on contingent considerations.

The Company is still in the process of finalizing the purchase price allocation for these acquisitions, and therefore, the balances are subject to change as a result of any working capital or fair value adjustments, and seller indemnification obligations. The following table summarizes the preliminary purchase price allocation of the fair value of assets acquired and liabilities assumed related to each acquisition at the acquisition date (in thousands):

			CFC						AHMS						Others *						Net  Total
Total purchase consideration:
Cash paid			$	90,998					$	—					$	12,500					$	103,498
Cash payable			—						63,935						—						63,935
Contingent consideration			7,264						—						5,897						13,161
Common stock issued			21,952						—						—						21,952
			$	120,214					$	63,935					$	18,397					$	202,546
Assets:
Cash and cash equivalents			$	16,674					$	33,950					$	3,515					$	54,139
Investment in marketable securities			50						—						30						80
Receivables			5,351						11,847						—						17,198
Prepaid expenses and other current assets			—						36						11						47
Amounts due from affiliates			3,909						—						—						3,909
Land, property and equipment			—						—						823						823
Intangible assets			26,000						23,800						2,703						52,503
Goodwill			90,148						29,876						12,318						132,342
Restricted cash			—						300						—						300
Total identifiable assets acquired			$	142,132					$	99,809					$	19,400					$	261,341
Liabilities:
Accounts payable and accrued expenses			$	4,376					$	7,232					$	250					$	11,858
Medical liabilities			17,508						13,137						—						30,645
Amounts due to affiliates			—						7,241						54						7,295
Income taxes payable			34						1,604						—						1,638
Deferred tax liability			—						6,660						271						6,931
Noncontrolling interest			—						—						428						428
Total identified liabilities assumed			$	21,918					$	35,874					$	1,003					$	58,795
Total net identifiable assets acquired			$	120,214					$	63,935					$	18,397					$	202,546

    

* Others consist of estimated fair values of the assets acquired, net of cash acquired, related to ADSC and PCCCV.

Following the acquisition dates of CFC, AHMS, ADSC and PCCCV, the operating results have been included in our consolidated financial statements. For the period from the acquisition dates through March 31, 2024, total revenues and net income were $33.2 million and $5.1 million, respectively.

The pro forma financial information in the table below presents the combined results of the Company and CFC, AHMS, ADSC and PCCCV as if the acquisitions had occurred on January 1, 2023. The pro forma information presented is shown for illustrative purposes only and is not necessarily indicative of future results of operations of the Company or results of operations of the Company that would have actually occurred had the transactions been in effect for the periods presented.

The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. Factors leading to goodwill being recognized are the Company’s expectation of synergies from combining operations of entities acquired and the Company, as well as the value of intangible assets that are not separately recognized, such as assembled workforce. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company’s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.

At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.

Goodwill is not deductible for tax purposes. The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three months ended March 31, 2024 and 2023.

The change in the carrying value of goodwill for the three months ended March 31, 2024 was as follows (in thousands):

At March 31, 2024, the Company’s intangible assets, net, consisted of the following (in thousands):

At December 31, 2023, the Company’s intangible assets, net, consisted of the following (in thousands):

For the three months ended March 31, 2024 and 2023, the Company recognized amortization expenses of $4.4 million and $3.0 million, respectively, in depreciation and amortization on the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March 31, 2024 and 2023.

Future amortization expense is estimated to be as follows for the following years ending December 31 (in thousands):

For the three months ended March 31, 2024 and 2023, the Company’s equity method investment balance consisted of the following (in thousands):

* Other consists of smaller equity method investments.

** Investment were solely for the benefit of APC and its shareholders.

On March 31, 2024, a wholly owned subsidiary of the Company acquired a 25% equity interest in I Health, Inc. (“I Health”), a management service organization. The Company accounts for its investment in I Health under the equity method of accounting as the Company has the ability to exercise significant influence, but not control over I Health’s operations. The purchase agreement includes a call option that allows the Company to purchase an additional 25% equity interest on each of the first, second and third anniversary of the purchase (“I Health Call Option”). The cash consideration was not paid on the closing date, and was accrued and presented within accounts payable and accrued expenses and other liabilities in the accompanying condensed consolidated balance sheets.

There was no impairment loss recorded related to equity method investments for the three months ended March 31, 2024 and 2023.

In July 2023, the Company entered into a five-year convertible promissory note with IntraCare as the borrower. The principal on the note is $25.0 million, with interest on the outstanding principal amount and unpaid interest at a rate per annum equal to 8.81%, compounded annually. In the event that the convertible promissory note remains outstanding on or after the maturity date of July 27, 2028, the outstanding principal balance and any unpaid accrued interest shall, upon the election of the Company, convert into IntraCare preferred shares.

On January 29, 2024, the Company provided BASS Medical Group (“BASS”) with a $20.0 million senior secured promissory note (“BASS secured promissory note”). The promissory note is secured by certain assets of BASS. BASS secured promissory note matures on January 11, 2031, and has an interest rate per annum equal to 8.21% compounded annually. The principal on the note, including unpaid interest, are due and payable on the maturity date.

The Company assessed the outstanding loans receivable under the CECL model by assessing the party’s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any identified insolvency risk.

The Company’s accounts payable and accrued expenses consisted of the following (in thousands):